{
  "symbol": "ECOR",
  "company_name": "Electrocore Inc",
  "ir_website": "https://investor.electrocore.com/",
  "structured_data": [
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award",
          "url": "https://investor.electrocore.com/news-releases/news-release-details/electrocores-truvagatm-plus-wins-womans-world-magazine-50-over",
          "content": "[Skip to content](#lfg-main-content)\n\n# \n\nelectroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award\n\nNovember 20, 2024 at 8:00 AM EST\n\nROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been recognized in the inaugural Woman’s World Magazine 50 over 50 Award. Products were evaluated based on quality, effectiveness, and value, with these awards honoring outstanding products for women over 50. A link to the article can be found here: Woman’s [World 50 Over 50 Awards](https://www.globenewswire.com/Tracker?data=0Deb0S8mUttMlRkgGV0GXqbugox726tZeUh5PXznL3NiUUQM-MEOib_OtZMaoIvyA1Gw92e7o5YNS7gD1JObSkTgjQmQ00M57ZoXX99U-TtjMxXSgu-Nc9P_snt1KCY5r1Ij7QC3PfC1wIQoFOtqIKnA1n4BABZ5-Ky5NLAelFs=).\n\n“We are thrilled to receive the Woman’s World Magazine 50 over 50 Award for Truvaga Plus,” stated Dan Goldberger, CEO of electroCore. “This honor highlights our dedication to creating solutions that enhance quality of life by alleviating stress, improving sleep, and sharpening mental focus. We take great pride in Truvaga Plus being recommended by Woman’s World Magazine.”\n\n**About Woman’s World Magazine**Woman’s Magazine, published by a360media, is a beloved publication offering diverse content tailored to women’s interests. Known for its engaging and uplifting tone, the magazine covers a wide range of topics, including health, wellness, beauty, fashion, relationships, recipes, and inspirational stories. The magazine reaches a total audience of 5.2 million.\n\nFor more information, please visit [https://www.womansworld.com](https://www.globenewswire.com/Tracker?data=g6nt9-asmx87MGytGTpGMzApLg6P55Id7-bjBrnBEpGr9degJ1w1mBdodPS2VYGDpvwQo1DfbBuQiJW1pxtf1KGw7ouzGQko-sVt9x7ivr0=). Such website, and the information on such website, is neither part of this press release nor incorporated by reference herein.\n\n**About Truvaga Plus**\n\nTruvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company’s proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease.\n\nFor more information, please visit [www.truvaga.com](https://www.globenewswire.com/Tracker?data=QOpNye2rkMEtdpqfkN96SOD6pA61cCRT1iL5CM0JOwmuJUf-6h0R9Vjpg94DW58HzyqCzpfvJ_4xyc1fC-KP6Q==).\n\n**About electroCore, Inc.** electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. The company’s is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.\n\nFor more information, visit [www.electrocore.com](https://www.globenewswire.com/Tracker?data=e3d6th8lhk3-zb6BXJaBsqDqQls4-iJ_jhSTDKeUiSfiFkI-ftOqshYn_LbtKn-KvwK4aLvQGStNMfLmqGefAwZ5rko2EcO5FkM12wm78yA=).\n\n**Forward-Looking Statements**\n\nThis press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, new and existing wellness product offerings, new ecommerce site, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including focus group study results; the Company’s business prospects in the United States (including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as \"anticipates,\" \"will,\" \"expects,\" \"believes,\" \"intends,\" other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the ability to successfully launch and commercialize Truvaga Plus, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at [www.sec.gov](https://www.globenewswire.com/Tracker?data=Qp5RWxnCB5Ncm2uBNnJhE-TXBa3FSaJzz1AyNovyf9rATXxk8DbVFykwdoYRmP65R-Z0JMBwVDK_ur8T2qigkw==).\n\n**Contact:** ECOR Investor Relations(973) 302-9253investors@electrocore.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3NjgzOSM2NTkxNjA4IzIwOTg3NDQ=)![](https://ml.globenewswire.com/media/Njg0YjkzZTgtMWNhZC00ODQ1LTg2NWYtMzhmMzg0ZTA4ZWUzLTExMTAzMTU=/tiny/electroCore-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b80ed5b6-a449-461c-9034-85386286b09d)\n"
        },
        {
          "title": "electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis",
          "url": "https://investor.electrocore.com/news-releases/news-release-details/electrocore-donates-gammacore-sapphire-real-world-evaluation",
          "content": "[Skip to content](#lfg-main-content)\n\n# \n\nelectroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis\n\nNovember 19, 2024 at 8:00 AM EST\n\nROCKAWAY, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has donated 20 gammaCore Sapphire D’s to be used by Dr. Robin Ely, Director of Integrative and Regenerative Medicine, a global practice focused on the development of integrated treatment regimens for neurocognitive and neurodegenerative disorders, and Dr. Yori Gidron, professor of health psychology at the Dept. of Nursing, Faculty of welfare and health sciences, University of Haifa and co-author of the PTSD Clinical Practice Guideline published by the Vagus Nerve Society. The real-world evaluation will be conducted by Dr. Gidron among Israelis dealing with trauma.\n\nPeter Staats, MD, Chief Medical Officer of electroCore, commented, “PTSD remains a serious condition affecting the general population, and especially veterans and members of active-duty military, with limited therapeutic options. We are greatly appreciative of the opportunity to work with Dr. Gidron and Dr. Ely who helped coordinate this cross-border effort.”\n\nDr. Yori Gidron, study coordinator, commented, “PTSD is a debilitating psychiatric condition stemming from exposure to traumatic events which impact daily life and mental well-being. Non-invasive vagus nerve stimulation (nVNS) presents a novel therapeutic solution, and we appreciate electroCore’s donation of their gammaCore Sapphire devices to conduct this real-world evaluation.”\n\nFor more information on the PTSD Clinical Guideline, visit: [VNS Society PTSD Clinical Guideline](https://www.globenewswire.com/Tracker?data=JZVHchw6E_7KG0Le8ALvvRalD8m26OO5ZNTYJ01klT_jRtTOK2hMvg9Am1t67zUC_GabU2_n-Lg71WEAJmXrsBLIP2bHLCzWcOTNLoFfYo8cNyiJO1u6ADUgo8aMlMkMRTmRtvrKwdcgKM585OmHkWPWMLqPzo4AiDnstbWA3es=).\n\n**About the Vagus Nerve Society**The Vagus Nerve Society is a multidisciplinary global non-profit for all clinicians dedicated to the ongoing education and training of scientists and clinicians in the power of the vagus nerve and its application in a broad spectrum of health-related conditions.\n\nTo learn more, please visit [https://www.vnsociety.org/](https://www.globenewswire.com/Tracker?data=6FLwLdQ9EAP5x5_ASpCzSvUPUsk9PZV8enFo3nq71SzB1foaKJnWDnKO2CBKOrtUtKP_anZj9FPf6E1d6S9lpZRcsGK9yD00NBRzGSdsC0M=)\n\n**About electroCore, Inc.** electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.\n\nFor more information, visit [www.electrocore.com](https://www.globenewswire.com/Tracker?data=iCusHHjxyZeTm0Wej2R-MJGbs2UqITGk4gP23t8rwHrRospomIG_L8l_knpJ5DPghcFNXaHqFfOOZbHpU45dEou4JnFrxaakbIwDhVCZFS8=).\n\n**Forward-Looking Statements** This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the use of gammaCore Sapphire for symptoms of PTSD, electroCore's business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally in particular to accelerate training, and other statements that are not historical in nature, particularly those using terminology such as \"anticipates,\" \"expects,\" \"believes,\" \"intends,\" other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize nVNS products, competition in the industry in which electroCore operates and general market conditions. The results of preclinical studies and clinical trials may not be predictive of results of future preclinical studies, clinical trials, or commercial success. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at [www.sec.gov](https://www.globenewswire.com/Tracker?data=hkPkrTkbpwDzwSdSB3jX0S5ESCYmt6aa9WWAq4qrhRjWPIU3H8DDpD1IYkjyLEvVpsI_92NVTymzS-eVZ8lfXQ==).\n\n**Contact** ECOR Investor Relations(973) 302-9253[investors@electrocore.com](https://www.globenewswire.com/Tracker?data=haka59qaVU65yAKllVfqFU7IflCBSai7ScaWZ_m0ygZEZyeNSSi-MQUX8akkkjtMpgtb_EFS4FMSUNmX5okjCNwEwlVOkMFXFr_EcNfIgRGYUOQzs1-8JvD0-v4blVrt)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3NjE0MCM2NTg5ODkxIzIwOTg3NDQ=)![](https://ml.globenewswire.com/media/YTVmODhjZjctZmFhNy00MmU0LThiOTEtOWY1MzlmNDg5NWYxLTExMTAzMTU=/tiny/electroCore-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b80ed5b6-a449-461c-9034-85386286b09d)\n"
        },
        {
          "title": "electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21",
          "url": "https://investor.electrocore.com/news-releases/news-release-details/electrocore-participate-canaccord-genuity-medtech-diagnostics-0",
          "content": "[Skip to content](#lfg-main-content)\n\n# \n\nelectroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21\n\nNovember 14, 2024 at 8:00 AM EST\n\nROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024.\n\nJoshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day.\n\nTo schedule a one-on-one meeting with Mr. Lev, investors are encouraged to reach out to their CG representative. For more information regarding the event please visit [https://www.meetmax.com/sched/event_110807/conference_home.html](https://www.globenewswire.com/Tracker?data=9aKgB_OReEy0nl9IDVSd7VXLlc_KXpoSHKeGJPZelv7MYl4nLUh_ckS-1Pc9Bwt6-V5OwjhzqrHTSOQ4-tOFq6kOqh3MVn2FB3H9gdYct1ZbTIv-kMnLvcfWXdk9Q5orEm5RRDcvvvIiRnQMgKoxmEwruEbbcCprbezIh7dnbcHEBFt0AQA2_QRPJv1nM-fczuai8COXwOnq1AeVd2rpSw==).\n\n**About electroCore, Inc.** electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.\n\nFor more information, visit [www.electrocore.com](https://www.globenewswire.com/Tracker?data=AkHQRYrkDyyCz_bUge0CIpvRmOES7FdVTKVefX-2YJ7WoREF6sLe2IcnNhVfofxIZzY-t5Kq1gyMdsZZdsMviyH5e3bAtwlVhMpXU5nFluA=).\n\n**Contact**\n\nECOR Investor Relations(973) 302-9253[investors@electrocore.com](https://www.globenewswire.com/Tracker?data=512OIszQnbQJFVXrLr45YMVWimPlUIxKx86wY3NfOXXa2Z2OOm3JNx6wWnWGcYsERf6XtL32qbiwuTuXwbSu_H7YeQyBSh0OkmIOqeqi8IOKuNynBCK8PpdFDIuUNlfa)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MDc1MyM2NTc0NDc0IzIwOTg3NDQ=)![](https://ml.globenewswire.com/media/YWEyMzBkYzMtMTYxNy00ZDMwLWEyYmItZDVmZmZlZDIyNTU4LTExMTAzMTU=/tiny/electroCore-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/b80ed5b6-a449-461c-9034-85386286b09d)\n"
        }
      ]
    },
    {
      "section_name": "Events and Presentations",
      "links": [
        {
          "title": "Third Quarter 2024 Financial Results",
          "url": "https://event.choruscall.com/mediaframe/webcast.html?webcastid=qH6ud5sW",
          "content": "### Warning\n\nClose\n\n# electroCore Third Quarter 2024 Earnings\n\n#### Wednesday, November 13, 2024 at 4:30 PM EST\n\nTo view this presentation, provide the requested information below.\n\nFirst name*\n\nLast name*\n\nEmail*\n\nCompany*\n\nSubmit\n\nYour data will be processed according to the European GDPR, the Swiss LPD, and the Brazilian LGPD. For more information, please refer to the Chorus Call website.\n\n© 2024 electroCore, Inc.\n\n![Cece logo](https://78449.choruscall.com/dataconf/dmf/1.5.3/images/helpdesk/cece_logo_circle.png)\n\n**Webcast Support**\n\nOnline Now\n\n![Cece logo](https://78449.choruscall.com/dataconf/dmf/1.5.3/images/helpdesk/cece_text_logo.png)\n"
        },
        {
          "title": "LD Micro Main Event XVII 2024",
          "url": "https://me24.sequireevents.com/",
          "content": "\n"
        },
        {
          "title": "Maxim Virtual Healthcare Summit",
          "url": "https://m-vest.com/events/healthcare-10152024",
          "content": "Days\n\nHours\n\nMinutes\n\nSeconds\n\nLog In or Sign Up \n\nSponsors\n\n![](https://mvest-prod.s3.amazonaws.com/assets/Maxim+Group+LLC+Logo+White.svg)\n\n![](https://rdcdn.com/rt?aid=21488&e=1&img=1) ![](https://t.co/i/adsct?bci=3&dv=Asia%2FCalcutta%26en-US%26Google%20Inc.%26Win32%26255%261920%261080%2616%2624%261920%261080%260%26na&eci=2&event_id=0d1a27c7-7a82-45d9-a49f-775eb4716cf1&events=%5B%5B%22signup%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=0d9cb8f5-ae8a-483e-8c62-a5e39d3d7bae&tw_document_href=https%3A%2F%2Fm-vest.com%2Fevents%2Fhealthcare-10152024&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5n6f&type=javascript&version=2.3.31)![](https://analytics.twitter.com/i/adsct?bci=3&dv=Asia%2FCalcutta%26en-US%26Google%20Inc.%26Win32%26255%261920%261080%2616%2624%261920%261080%260%26na&eci=2&event_id=0d1a27c7-7a82-45d9-a49f-775eb4716cf1&events=%5B%5B%22signup%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=0d9cb8f5-ae8a-483e-8c62-a5e39d3d7bae&tw_document_href=https%3A%2F%2Fm-vest.com%2Fevents%2Fhealthcare-10152024&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5n6f&type=javascript&version=2.3.31)\n"
        }
      ]
    }
  ]
}